Jade Biosciences, Inc. announces its 2026 strategic priorities at the 44th Annual J.P. Morgan Healthcare Conference.
The company focuses on developing best-in-class therapies for autoimmune diseases.
Key milestones include ongoing Phase 1 trials, initiation of Phase 2 trials, and advancing new development candidates.
JADE101 Phase 1 Trial
Ongoing healthy volunteer trial with anticipated interim data in the first half of 2026.
JADE201 in Rheumatoid Arthritis
Expected to advance into first-in-human study in the second quarter of 2026.
JADE301 Development
New development candidate nominated, expected to start Phase 1 trial in the first half of 2027.
- Jade Biosciences aims to deliver deeper efficacy with a lower treatment burden for patients.
- The company's strong balance sheet is expected to provide runway into the first half of 2028, supporting continued growth and value creation.
Jade Biosciences is positioned for rapid growth in 2026 with a focused strategy and a promising pipeline of monoclonal antibodies.